A Gain‐of‐Function Variant in Dopamine D2 Receptor and Progressive Chorea and Dystonia Phenotype
暂无分享,去创建一个
K. Neve | John T. Williams | M. Tijssen | C. Delnooz | D. Verbeek | G. Stormezand | Alec F. Condon | Claudia Dufke | K. Ma | Marlous C M van der Weijden | D. Rodríguez-Contreras | Brooks G. Robinson | Michelle L Kielhold
[1] K. Neve,et al. Arrestin recruitment to dopamine D2 receptor mediates locomotion but not incentive motivation , 2018, Molecular Psychiatry.
[2] A. Mishra,et al. Physiological and Functional Basis of Dopamine Receptors and Their Role in Neurogenesis: Possible Implication for Parkinson’s disease , 2018, Journal of experimental neuroscience.
[3] I. Pavlova,et al. Effects of Blockade of D1 and D2 Receptors in the Basolateral Amygdala on the Behavior of Rats with High and Low Levels of Anxiety and Fear , 2016, Neuroscience and Behavioral Physiology.
[4] V. Gurevich,et al. G protein-coupled receptor kinases as regulators of dopamine receptor functions. , 2016, Pharmacological research.
[5] Jung Hoon Shin,et al. Enhanced GABA Transmission Drives Bradykinesia Following Loss of Dopamine D2 Receptor Signaling , 2016, Neuron.
[6] Sylvain Houle,et al. Lack of Age-Dependent Decrease in Dopamine D3 Receptor Availability: A [11C]-(+)-PHNO and [11C]-Raclopride Positron Emission Tomography Study , 2015, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[7] T. Daigle,et al. Targeting β-arrestin2 in the treatment of l-DOPA–induced dyskinesia in Parkinson’s disease , 2015, Proceedings of the National Academy of Sciences.
[8] R. Barker,et al. Movement disorders and psychiatry: Five new things. , 2015, Neurology. Clinical practice.
[9] A. Schapira,et al. Pathogenic mechanisms of neurodegeneration in Parkinson disease. , 2015, Neurologic clinics.
[10] J. Javitch,et al. Upregulation of Dopamine D2 Receptors in the Nucleus Accumbens Indirect Pathway Increases Locomotion but Does Not Reduce Alcohol Consumption , 2015, Neuropsychopharmacology.
[11] K. Neve,et al. Mutation of Three Residues in the Third Intracellular Loop of the Dopamine D2 Receptor Creates an Internalization-defective Receptor* , 2014, The Journal of Biological Chemistry.
[12] John T. Williams,et al. Spontaneous Inhibitory Synaptic Currents Mediated by a G Protein-Coupled Receptor , 2013, Neuron.
[13] T. Sotnikova,et al. Beyond cAMP: The Regulation of Akt and GSK3 by Dopamine Receptors , 2011, Front. Mol. Neurosci..
[14] J. Beaulieu,et al. Role of Beta-Arrestin 2 Downstream of Dopamine Receptors in the Basal Ganglia , 2011, Front. Neuroanat..
[15] A. Korchounov,et al. Postsynaptic nigrostriatal dopamine receptors and their role in movement regulation , 2010, Journal of Neural Transmission.
[16] C. Lüscher,et al. Emerging roles for G protein-gated inwardly rectifying potassium (GIRK) channels in health and disease , 2010, Nature Reviews Neuroscience.
[17] K. Neve,et al. A Dopamine D2 Receptor Mutant Capable of G Protein-Mediated Signaling but Deficient in Arrestin Binding , 2007, Molecular Pharmacology.
[18] John T. Williams,et al. Long-Term Depression of a Dopamine IPSC , 2007, The Journal of Neuroscience.
[19] R. Lefkowitz,et al. β-Arrestins and Cell Signaling , 2007 .
[20] C. Pagès,et al. Unraveling a role for dopamine in Huntington's disease: the dual role of reactive oxygen species and D2 receptor stimulation. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[21] D. Grandy,et al. Vesicular Dopamine Release Elicits an Inhibitory Postsynaptic Current in Midbrain Dopamine Neurons , 2004, Neuron.
[22] M. Brin,et al. Phenotypic features of myoclonus-dystonia in three kindreds , 2002, Neurology.
[23] Stephen J. Fink,et al. Evaluation of the role of the D2 dopamine receptor in myoclonus dystonia , 2000, Annals of neurology.
[24] A. Rossi,et al. The emergence of social phobia during clozapine treatment and its response to fluoxetine augmentation. , 1999, The Journal of clinical psychiatry.
[25] S Fahn,et al. Association of a missense change in the D2 dopamine receptor with myoclonus dystonia. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[26] M. Low,et al. Locomotor Activity in D2 Dopamine Receptor-Deficient Mice Is Determined by Gene Dosage, Genetic Background, and Developmental Adaptations , 1998, The Journal of Neuroscience.
[27] A. Saiardi,et al. Parkinsonian-like locomotor impairment in mice lacking dopamine D2 receptors , 1995, Nature.
[28] R. Rodgers,et al. Dopamine D1 and D2 receptor ligands modulate the behaviour of mice in the elevated plus-maze , 1994, Pharmacology Biochemistry and Behavior.
[29] P. Pauwels,et al. Review: Amino acid domains involved in constitutive activation of G-protein-coupled receptors , 2007, Molecular Neurobiology.
[30] K. Eidne,et al. Bioluminescence resonance energy transfer (BRET) for the real-time detection of protein-protein interactions , 2006, Nature Protocols.